You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CLL1-CD33 cCAR

Showing 1 - 25 of 5,007
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CLL1-CD33 cCAR T cells)

Recruiting
  • Hematologic Malignancy
  • +4 more
  • CLL1-CD33 cCAR T cells
  • Chengdu, China
  • +1 more
May 17, 2021

Acute Myeloid Leukemia Trial in Fuzhou (CLL1/+CD33 CAR-T)

Not yet recruiting
  • Acute Myeloid Leukemia
  • CLL1/+CD33 CAR-T
  • Fuzhou, Fujian, China
    Fujian Provincial Children's Hospital
Jul 10, 2023

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

Acute Myeloid Leukemia Trial in Wuxi (Anti-CD33/CLL1 CAR-NK Cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CD33/CLL1 CAR-NK Cells
  • Wuxi, Jiangsu, China
    Wuxi People's Hospital
Jan 18, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Acute Myeloid Leukemia Trial in Beijing (Dual CD33/CLL1 CAR T)

Recruiting
  • Acute Myeloid Leukemia
  • Dual CD33/CLL1 CAR T
  • Beijing, Beijing, China
    Beijing Boren Hospital
Feb 16, 2022

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

Leukemia, Myeloid, Acute Trial in Chongqing (Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • Chongqing, Chongqing, China
    Department of Hematology, Xinqiao Hospital
Aug 20, 2021

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

AML, Childhood Trial in United States (CD33*CD3 BsAb)

Active, not recruiting
  • AML, Childhood
  • CD33*CD3 BsAb
  • Birmingham, Alabama
  • +12 more
Jan 12, 2023

Leukemia, Myeloid, Acute Trial in United States (VCAR33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • VCAR33
  • La Jolla, California
  • +9 more
Aug 14, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • SC-DARIC33
  • Seattle, Washington
    Seattle Children's Hospital
Sep 6, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Baltimore, Maryland
  • +1 more
Dec 13, 2022

Leukemia, Myeloid, Acute Trial in Canada, United States (VOR33, Mylotarg)

Recruiting
  • Leukemia, Myeloid, Acute
  • La Jolla, California
  • +8 more
Jan 31, 2023

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory Trial in New York (EGFRt/19-28z/4-1BBL CAR T cells)

Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +2 more
  • EGFRt/19-28z/4-1BBL CAR T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 1, 2022

CLL/SLL, NHL, Mantle Cell Lymphoma Trial in United States (SYNCAR-001, STK-009, Cyclophosphamide)

Recruiting
  • CLL/SLL
  • +6 more
  • Duarte, California
  • +4 more
Jan 12, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
Mar 11, 2022

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

ECG, Pharmacokinetics, Safety Trial in Worldwide (Gemtuzumab Ozogamicin)

Completed
Has Results
  • ECG
  • +2 more
  • Gemtuzumab Ozogamicin
  • Augusta, Georgia
  • +23 more
Feb 28, 2022

Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CD123-CD33 cCAR T cells)

Unknown status
  • Hematologic Malignancy
  • +4 more
  • CD123-CD33 cCAR T cells
  • Chengdu, China
  • +1 more
Nov 8, 2019

Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Daratumumab
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022